MedWatch Offers Safety Alerts via Text

Article

The FDA has added text messaging to the ranks of e-mail digests, RSS feeds, podcasts, and Websites that comprise MedWatch, the agency's safety information and adverse event reporting program.

The FDA has added text messaging to the ranks of e-mail digests, RSS feeds, podcasts, and Websites that comprise MedWatch, the agency’s safety information and adverse event reporting program. The free 6-month pilot program sends registrants 3 to 5 weekly safety alerts. Signing up for MedWatch texts can keep busy oncologists informed on FDA safety concerns regarding medications, vaccines, and medical devices. Messages can be tailored during registration to suit individual needs. According to MedWatch medical director Norman S. Marks, MD, MHA, the service is the first step toward delivering targeted, patient-specific information that can be used to impact decisions at the point of care. The FDA’s ultimate aspiration, Marks said in a press statement, is for drug-specific safety alerts to coordinate with patients’ electronic health records. To sign up for the service, text FDA in the body of the message to 87000. While the FDA does not charge subscribers to participate in this pilot program, standard text messaging rates from the subscriber’s wireless carrier may apply. For more information on MedWatch, visit www.fda.gov/Safety/MedWatch/default.htm.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
A panel of 5 experts on iron deficiency anemia
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Phase 2 Data Shows KP1077 Meaningfully Improves Idiopathic Hypersomnia Symptoms
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
© 2024 MJH Life Sciences

All rights reserved.